Lisanti Capital Growth’s Corcept Therapeutics CORT Stock Holding History

Lisanti Capital Growth’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.97M	Buy	+91,610	New	+$5.53M	1.75%	5
2025 Q4	–	Sell	-68,273	Closed	-$5.67M	–	119
2025 Q3	$5.67M	Buy	68,273 +21,913	+47%	+$1.59M	1.39%	25
2025 Q2	$3.4M	Sell	46,360 -53,100	-53%	-$3.85M	0.94%	47
2025 Q1	$11.4M	Buy	99,460 +21,795	+28%	+$1.33M	3.38%	1
2024 Q4	$3.91M	Sell	77,665 -35,490	-31%	-$1.86M	0.94%	50
2024 Q3	$5.24M	Buy	113,155 +50,160	+80%	+$1.78M	1.33%	22
2024 Q2	$2.05M	Buy	+62,995	New	+$1.73M	0.49%	80

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lisanti Capital Growth's CORT Position: Q2 2026 in Review

Lisanti Capital Growth opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 91,610 shares worth $7.97M. The stake represents 1.75% of the portfolio and ranks #5 among its holdings. This is a return to the name: Lisanti Capital Growth previously reported a position in CORT as recently as Q3 2025.

Lisanti Capital Growth first reported a position in CORT in Q2 2024 and has held it in 7 quarters since. The position peaked at $11.4M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Lisanti Capital Growth held 91,610 shares of Corcept Therapeutics worth $7.97M as of Q2 2026.
Corcept Therapeutics was a new Lisanti Capital Growth position in Q2 2026.
Corcept Therapeutics made up 1.75% of Lisanti Capital Growth's portfolio in Q2 2026, its #5 holding.
Lisanti Capital Growth first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 7 quarters since.
Lisanti Capital Growth's Corcept Therapeutics position peaked at $11.4M in Q1 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Lisanti Capital Growth's 13F filing for Q2 2026, filed 10 Aug 2026.